‘Watch and Wait’ as Initial Management for Patients with Follicular Lymphomas

摘要: Observation until the development of symptoms, or ‘watch and wait’, has long been a proposed management technique for patients with indolent lymphomas. However, investigators have found that there may be differences in outcomes various patient groups according to histopathology, clinical features disease, biologic factors as yet fully recognized, type initial therapy offered. Recently, from UK National Cancer Research Institute reported progression-free results were significantly improved when asymptomatic follicular lymphomas received single-agent rituximab rather than they underwent observation alone. These further maintenance rituximab. Time chemotherapy was also longer these rituximab, thereby delaying need such treatment. overall survival rates who similar those wait’. Future studies should concentrate on risks management, including cost effectiveness treatments resistance subsequent therapies.